Author

D. V. Allegakoen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

T. G. Bivona· 2 shared A. J. Sabnis· 1 shared B. Huang· 1 shared C. E. McCoach· 1 shared C. Fernandez-Mendez· 1 shared C. Gomez· 1 shared C. J. Kuo· 1 shared C. M. Blakely· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

T. G. Bivona

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

D. V. Allegakoen, K. Kwong, J. Morales, T. G. Bivona, A. J. Sabnis

This study identifies DNAJC17 as an essential JDP that activates HSP70 to regulate RNA splicing and G2-M progression through structural domains.

bioRxiv · Oct 25, 2023Cell Biology

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

F. Haderk, C. Fernandez-Mendez, L. Cech, J. Yu, I. M. Meraz, V. Olivas, D. Barbosa Rabago, D. L. Kerr, C. Gomez, D. V. Allegakoen, J. Guan, K. N. Shah, K. A. Herrington, O. M. Gbenedio, S. Nanjo, , T. G. Bivona

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

bioRxiv · Oct 23, 2021Cancer Biology